UK Myasthenia Gravis Launch Readiness

Eculizumab (Soliris, AstraZeneca) is NICE's clearest cautionary precedent in rare disease: despite FDA and MHRA approval for gMG, the NICE appraisal (TA636, published 30 June 2020) was terminated before a cost-effectiveness review ever took place, because AstraZeneca never submitted the evidence NICE required — no ICER was modelled or published for the drug in this indication. The result is a UK gMG market with zero NICE-commissioned novel biologic: refractory patients (immunosuppressant-inadequate, MGFA Class II-IV) rely on IVIg maintenance and plasma exchange, with only case-by-case NHS Individual Funding Request access to eculizumab for the highest-risk 50-100 patients/year, an expensive, administratively heavy route NHS commissioning managers are motivated to retire.

Efgartigimod (Vyvgart Hytrulo, argenx), the first FcRn antagonist, cleared MHRA approval but NICE published its final guidance (TA1069) on 4 June 2025 declining to recommend it for NHS commissioning, extending the sector's access drought: no FcRn antagonist has yet cleared NICE's price bar in gMG. Of an estimated 12,000-15,000 UK gMG patients, 2,000-3,000 are refractory to immunosuppressant therapy and represent significant pent-up demand, a population that has now watched two consecutive gMG biologics fail to secure NHS commissioning. The IVIg backbone these patients currently receive costs the NHS an estimated £1.5-5 million/year in gMG alone and has been subject to supply-chain rationing, adding institutional motivation toward a novel-biologic alternative that can actually clear NICE's threshold.

The pre-launch design task is explicit: eculizumab's failure to reach NICE commissioning shows the WAC and PAS must be dramatically lower than £200,000/year from the outset, and modelling suggests an effective NHS price of £40,000-78,000/year (a 45-55% PAS off an £80,000-120,000/year WAC) is the range that clears NICE's standard threshold once IVIg cost-offset (£5,000-10,000/patient/year) and subcutaneous administration savings (£3,000-5,000/patient/year vs IV) are credited into the model. Subcutaneous formulation is not optional for a competitive UK submission. Sponsor MAGS UK's refractory-gMG patient survey roughly 12 months ahead of NICE submission (typical budget £25,000-50,000), and engage the Association of British Neurologists' MG guideline committee 18-24 months pre-submission — both are direct NICE evidence inputs. The efgartigimod TA1069 rejection (June 2025) is now the FcRn access precedent any new drug will be measured against.

This assessment synthesises three research angles into a single UK gMG launch readiness view: competitive positioning against eculizumab and efgartigimod, refractory-population sizing anchored in MAGS UK survey data, and anticipated NICE/NHS payer posture derived from the published eculizumab termination and efgartigimod rejection decisions.

Sources: NICE eculizumab gMG termination decision document (TA636); NICE efgartigimod appraisal GID-TA10986 and final guidance TA1069; MAGS UK annual membership survey; Association of British Neurologists MG clinical guideline; NHSBT IVIg Demand Management Programme gMG data 2023; NHS England Individual Funding Request policy documentation.